Subject Predicate Object
frlS2JRG
a
Resource
Answer
Written answer
answer has question
KkvNZGSJ
answer has answering person
Stephen Charles Brine
answer text
<p>The National Institute for Health and Care Excellence (NICE) updated its guidance on ‘Early and locally advanced breast cancer: diagnosis and management’ in July 2018. The use of adjuvant bisphosphonates was one of the key areas that was covered in the update. NICE’s updated recommendations can be found at the following link:</p><p> </p><p><a href="https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#bisphosphonate-therapy" target="_blank">https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#bisphosphonate-therapy</a></p><p> </p><p>The guideline recommends bisphosphonates as adjuvant therapy for postmenopausal women with node positive invasive breast cancer and for postmenopausal women with node negative breast cancer.</p><p> </p><p>NICE also updated its guidance on the use of bisphosphonates for treating osteoporosis in February 2018. The updated guidance can be found at the following link:</p><p> </p><p><a href="https://www.nice.org.uk/guidance/ta464" target="_blank">https://www.nice.org.uk/guidance/ta464</a></p><p> </p><p>NICE recommends oral bisphosphonates for treating osteoporosis in adults if the person is eligible for risk assessment and the 10 year probability of osteoporotic fragility fracture is at least 1%.</p>
answer given date
answer has answering body
Department of Health and Social Care
written answer has answering body
Department of Health and Social Care
Department of Health and Social Care
answering body has written answer
frlS2JRG
answering body has answer
frlS2JRG
KkvNZGSJ
question has answer
frlS2JRG
Stephen Charles Brine
answering person has answer
frlS2JRG